晨光生物
(300138)
| 流通市值：36.45亿 | | | 总市值：44.20亿 |
| 流通股本：3.98亿 | | | 总股本：4.83亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 5,225,428,968.08 | 3,490,929,927.87 | 1,732,327,232.51 | 6,871,515,007.68 |
| 营业收入 | 5,225,428,968.08 | 3,490,929,927.87 | 1,732,327,232.51 | 6,871,515,007.68 |
| 二、营业总成本 | 5,127,064,914.93 | 3,408,448,437.38 | 1,687,056,795.93 | 6,450,813,191.25 |
| 营业成本 | 4,840,074,864.79 | 3,201,829,609.02 | 1,590,135,324.56 | 6,073,599,318.08 |
| 税金及附加 | 13,344,104.62 | 8,801,877.36 | 3,894,473.22 | 16,771,739.78 |
| 销售费用 | 33,687,842.99 | 26,065,300.95 | 13,676,490.25 | 61,075,598.21 |
| 管理费用 | 113,593,225.02 | 79,586,672.47 | 34,633,265.94 | 154,612,330.46 |
| 研发费用 | 72,436,744.27 | 47,913,591.56 | 23,149,384.73 | 97,400,025.19 |
| 财务费用 | 53,928,133.24 | 44,251,386.02 | 21,567,857.23 | 47,354,179.53 |
| 其中:利息费用 | 83,833,064.72 | 65,144,695.63 | 31,754,697.59 | 83,507,323.17 |
| 其中:利息收入 | 32,025,126.67 | 19,046,226.89 | 9,921,600.28 | 35,633,978.21 |
| 加:公允价值变动收益 | 1,121,316.72 | -6,447,474.73 | -38,867,464.25 | 5,363,332.98 |
| 加:投资收益 | 7,271,875 | 15,988,000.75 | 32,773,543.61 | 68,650,895.5 |
| 资产处置收益 | - | - | - | -632,753 |
| 资产减值损失(新) | -82,674,966.04 | -2,369,527.74 | -2,430,131.31 | 4,056,267.83 |
| 信用减值损失(新) | -312,056.38 | -700,644.32 | -154,726.49 | -1,126,405.44 |
| 其他收益 | 36,490,505.82 | 18,859,431.25 | 7,753,127.8 | 51,311,383.13 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 60,260,728.27 | 107,811,275.7 | 44,344,785.94 | 548,324,537.43 |
| 加:营业外收入 | 17,378,169.62 | 6,931,437.38 | 458,280.39 | 9,905,518.64 |
| 减:营业外支出 | 3,286,257.93 | 648,776.56 | 549,538.47 | 2,411,388.15 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 74,352,639.96 | 114,093,936.52 | 44,253,527.86 | 555,818,667.92 |
| 减:所得税费用 | 29,112,483.18 | 20,303,233.88 | 11,260,141.94 | 61,645,361.16 |
| 六、净利润 | 45,240,156.78 | 93,790,702.64 | 32,993,385.92 | 494,173,306.76 |
| 持续经营净利润 | 45,240,156.78 | 93,790,702.64 | 32,993,385.92 | 494,173,306.76 |
| 归属于母公司股东的净利润 | 62,605,888.08 | 99,834,623.94 | 38,591,936.61 | 479,722,222.22 |
| 少数股东损益 | -17,365,731.3 | -6,043,921.3 | -5,598,550.69 | 14,451,084.54 |
| (一)基本每股收益 | 0.12 | 0.19 | 0.07 | 0.9 |
| (二)稀释每股收益 | 0.12 | 0.19 | 0.07 | 0.9 |
| 八、其他综合收益 | -6,507,503.31 | 2,758,363.21 | 567,008.04 | 7,223,216.27 |
| 归属于母公司股东的其他综合收益 | -6,507,503.31 | 2,758,363.21 | 567,008.04 | 7,223,216.27 |
| 九、综合收益总额 | 38,732,653.47 | 96,549,065.85 | 33,560,393.96 | 501,396,523.03 |
| 归属于母公司股东的综合收益总额 | 56,098,384.77 | 102,592,987.15 | 39,158,944.65 | 486,945,438.49 |
| 归属于少数股东的综合收益总额 | -17,365,731.3 | -6,043,921.3 | -5,598,550.69 | 14,451,084.54 |
| 公告日期 | 2024-10-26 | 2024-08-27 | 2024-04-25 | 2024-04-18 |
| 审计意见(境内) | | | | 标准无保留意见 |